SEHK:1093Pharmaceuticals
Once‑Monthly Semaglutide And HER2 Data Could Be A Game Changer For CSPC Pharmaceutical Group (SEHK:1093)
CSPC Pharmaceutical Group recently reported two advances: U.S. FDA clearance to begin clinical trials of its once‑monthly semaglutide injection for weight management, and positive Phase III breast cancer data for its HER2 bispecific antibody regimen presented as a late‑breaking oral at the 2026 ASCO meeting.
Together, these developments spotlight CSPC’s efforts to build a differentiated pipeline in obesity and oncology, targeting large global treatment areas with clinically sophisticated...